ClinConnect ClinConnect Logo
Search / Trial NCT06929143

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Launched by BAYER · Apr 8, 2025

Trial Information

Current as of July 09, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called aflibercept in people with two eye disorders: neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Both conditions can cause blurry vision and are treated with aflibercept, which is injected into the eye to help improve vision. The goal of the study is to gather information about how Japanese patients with these conditions are treated with aflibercept in their regular healthcare settings. Researchers will look at health details when patients first start the treatment and track their progress over a year.

To be eligible for this study, participants need to be prescribed aflibercept 8 mg and must be between the ages of 65 and 74. The study will only collect data from patients already receiving this treatment, so no extra visits or tests are required. This research aims to provide more insights into how aflibercept is used in Japan, which can help improve care for patients in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who are prescribed aflibercept 8 mg during the observable period from the collected data.
  • Exclusion Criteria:
  • Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged \<40 years old.
  • Patients in the DME cohort or others who are aged \<18 years old.
  • Female patients who have any pregnancy-related records.
  • Patients who do not have at least 365 days of continuous enrollment in the database.

About Bayer

Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.

Locations

Osaka, , Japan

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported